1-(3-吗啉丙基)-2-硫脲 | 111538-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 1-(3-吗啉丙基)-2-硫脲
• 英文名称: 3-(morpholin-4-yl)propylthiourea
• 英文别名: 1-(3-morpholinopropyl)-2-thiourea；N-(3-morpholinopropyl)thiourea；1-[3-(4-morpholino)propyl]thiourea；3-morpholin-4-ylpropylthiourea
• CAS: 111538-46-6
• 化学式: C₈H₁₇N₃OS
• mdl: MFCD00041378
• 分子量: 203.308
• InChiKey: ZAANQRSELTXKBG-UHFFFAOYSA-N

物化性质

• 熔点：
  129 °C
• 沸点：
  339.5±52.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  82.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  1-(3-吗啉丙基)-2-硫脲 在 sodium hydride 作用下， 以 1,4-二氧六环 、 乙醇 、 mineral oil 为溶剂， 反应 9.0h， 生成 ethyl 2-[(6-chloro-5-methylpyridazin-3-yl)[3-(morpholin-4-yl)propyl]amino]-1,3-thiazole-4-carboxylate
  参考文献：
  名称：

  WO2021018857A5

  摘要：

  公开号：

  WO2021018857A5
• 作为产物：
  描述：

  3-(4-吗啉基)丙基异硫氰酸酯 在 氨 作用下， 以 乙二醇二甲醚 为溶剂， 以99%的产率得到1-(3-吗啉丙基)-2-硫脲
  参考文献：
  名称：

  Continuous-Flow Processing of Gaseous Ammonia Using a Teflon AF-2400 Tube-in-Tube Reactor: Synthesis of Thioureas and In-Line Titrations

  摘要：

  A simple tube-in-tube reactor based on the gas-permeable membrane Teflon AF-2400 was used in the continuous flow reaction of gaseous ammonia with isothiocyanates and one isocyanate. A colourimetric in-line titration technique is also reported as a simple method to quantify the amount of ammonia taken up by the solvent in the system.

  DOI：

  10.1055/s-0031-1290963

文献信息

• [EN] THIAZOLE AND OXAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE À BASE DE THIAZOLE ET D'OXAZOLE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009076140A1

  公开（公告）日：2009-06-18

  The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供了噻唑和恶唑化合物、含有该化合物的组合物，以及它们的制备方法和作为药物的应用方法。
• 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
  申请人：Dickson K. John

  公开号：US20060052416A1

  公开（公告）日：2006-03-09

  2-Amido-4-substituted-aryl-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.

  基于2-氨基-4-取代芳基噻唑的化合物展现出ATP利用酶抑制活性，公开了利用展现出ATP利用酶抑制活性的化合物的方法，以及包含展现出ATP利用酶抑制活性的化合物的组合物。
• Method and composition for rejuvinating cells, tissues organs, hair and nails
  申请人：——

  公开号：US20020188015A1

  公开（公告）日：2002-12-12

  In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

  在一个实施例中，本发明涉及包含药物组合物的化合物和组合物，其中药物组合物包含这些化合物，并且相关方法解耦蛋白质、脂质、核酸和其他生物材料以及它们的任意组合的糖介导偶联。在另一个实施例中，这些组合物和相关方法在体内具有实用性，用于减少生物体暴露于内部摄入、经皮应用或其他方式的化合物或组合物时，糖介导偶联过程的有害影响。在另一个实施例中，这些组合物和相关方法对器官、细胞和组织的离体处理以及头发、指甲和皮肤的外部处理具有用处，通过改变可变性和增加组织扩散系数来使它们恢复活力。在另一个实施例中，本发明涉及新颖的化合物和药物组合物。
• Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
  申请人：——

  公开号：US20030105071A1

  公开（公告）日：2003-06-05

  One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various mammalian cellular receptors, including G-protein coupled receptors. A third aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors or transporters. Another aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, Tourette's syndrome, psychiatric disorders, stroke, senile dementia, peptic ulcers, pulmonary obstruction disorders, and asthma.

  本发明的一个方面涉及新颖的杂环化合物。本发明的第二个方面涉及将这些新颖的杂环化合物用作各种哺乳动物细胞受体的配体，包括G蛋白偶联受体。本发明的第三个方面涉及将这些新颖的杂环化合物用作哺乳动物多巴胺、肌肉或血清素受体或转运体的配体。本发明的另一个方面涉及将这些新颖的杂环化合物用作哺乳动物多巴胺、肌肉或血清素受体的配体。本发明的化合物还将用于治疗许多困扰哺乳动物的疾病、症状和疾病，包括但不限于成瘾、焦虑、抑郁、性功能障碍、高血压、偏头痛、阿尔茨海默病、肥胖、呕吐、精神病、镇痛、精神分裂症、帕金森病、不宁腿综合征、睡眠障碍、注意力缺陷多动障碍、肠易激综合征、早泄、月经痛综合征、尿失禁、炎症性疼痛、神经痛、Lesche-Nyhane病、威尔逊病、抽动症、精神障碍、中风、老年性痴呆、消化性溃疡、肺阻塞疾病和哮喘。
• Benign Synthesis of Thiazolo-androstenone Derivatives as Potent Anticancer Agents
  作者：Mohamad Akbar Ali、ChrisTina Okolo、Zakeyah A. Alsharif、Jedidiah Whitt、Steven A. Chambers、Rajender S. Varma、Mohammad A. Alam

  DOI：10.1021/acs.orglett.8b02587

  日期：2018.9.21

  been rationalized by density functional theory calculations. This benign methodology accentuates a domino protocol deploying a renewable solvent, ethanol, while generating novel compounds that display potent growth inhibitory effects in in vitro studies for several cancer cell lines at submicromolar concentrations.

  已发现硫脲衍生物与6β-溴代雄烯二酮的空前反应可通过一种简单，安全，级联的方法形成氨基噻唑基-雄烯二酮，该协议能够通过使用现成的试剂合成新分子。通过密度泛函理论计算已经合理化了产物形成的反应机理。这种良性方法强调了使用可再生溶剂乙醇的多米诺协议，同时生成了在亚微摩尔浓度的几种癌细胞体外研究中显示出有效生长抑制作用的新型化合物。